Consistent with our results, IDH1/2 mutations have been shown to be factors indicating a favorable prognosis in all types of gliomas (Yan et al., 2009; Cancer Genome Atlas Research Network et al., 2015; Aibaidula et al., 2017). The gene discussed is IDH1; the disease is central nervous system cancer.